Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy

Clinical Nephrology

Volumn 64, Issue 3, 2005, Pages 180-189

  Matos, J P S ^a   de Lourdes Rodrigues, M ^a   Ismerim, V L ^a   Boasquevisque, E M ^a   Genelhu, V ^a   Francischetti, E A ^a,b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

Aldosterone; Diabetes; Nephropathy; Proteinuria; Transforming growth factor 1

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CLONIDINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INSULIN; IRBESARTAN; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; POTASSIUM; RENIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY PLASMA FLOW; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PERIPHERAL VASCULAR DISEASE; PLASMA RENIN ACTIVITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE; XEROSTOMIA;

EID: 24644492370     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp64180     Document Type: Article

References (31)

1. Abbate M, Zoja C, Rottoli D, Corna D, Tomasoni S, Remuzzi G 1999 Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol 10: 804-813
2. Abraham PA, Halstenson CE, Matzke GR, Keane WF 1987 Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy. J Clin Hypertens 3: 439-451
3. Agarwal R, Siva S, Dunn SR, Sharma K 2002 Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels. Am J Kidney Dis 39: 486-492
4. Brandstrom E, Grzegorczyk A, Jacobsson, Friberg P, Lindahl A, Aurell M 1998 GFR measurement with iohexol and 51-Cr-EDTA. A comparison of the favoured GFR markers in Europe. Nephrol Dial Transplant 13: 1176-1182
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
6. Brochner-Mortensen J 1972 A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30: 271-274
7. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P 2003 Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63: 1094-1103
8. Christensen PK, Lund S, Parving HH 2001 Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. Kidney Int 60: 1435-1442
9. Crowe AV, Howse M, Vinjamuri S, Kemp GJ, Williams PS 2003 The antiproteinuric effect of losartan is systemic blood pressure dependent. Nephrol Dial Transplant 18: 2160-2164
10. Honkaken E, Teppo AM, Tornroth T, Groop PH, Gronhagen-Riska C 1997 Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant 12: 2562-2568
11. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE 2002 Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 25: 1072-1077
12. Iodice C, Balletta MM, Minutolo R, Giannattasio P, Tuccillo S, Bellizzi V, D'Amora M, Rinaldi G, Signoriello G, Conte G, De Nicola L 2003 Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. Kidney Int 63: 2214-2221
13. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH 2002 Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17: 1019-1024
14. Junaid A, Rosenberg ME, Hostetter TH 1997 Interaction of angiotensin II and TGF-beta 1 in the rat remnant kidney. J Am Soc Nephrol 8: 1732-1738
15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462
16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860
17. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME 2000 Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 321: 1440-1444
18. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T 2003 Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117-124
19. Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, Ha SH, Lee HY, Han DS 2003 Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. Nephrol Dial Transplant 18: 1115-1121
20. Parving HH, Hommel E, Jensen BR, Hansen HP 2001 Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 60: 228-234
21. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C 2000 ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 57: 274-281
22. Praga M, Andrade CF, Luno J, Arias M, Poveda R, Mora J, Prat MV, Rivera F, Galceran JM, Ara JM, Aguirre R, Bernis C, Marin R, Campistol JM 2003 Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 18: 1806-1813
23. Rossing K, Jacobsen P, Pietraszek L, Parving HH 2003 Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover. Diabetes Care 26: 2268-2274
24. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G 1999 Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364
25. Schjoedt JK, Andersen S, Rossing P, Tarnow L, Parving HH 2003 Aldosterone escape during angiotensin II receptor blockade in diabetic nephropathy is associated with enhanced decline in GFR [Abstract]. J Am Soc Nephrol 14: 7A
26. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS 1997 Increased renal production of transforming growth factor-beta-1 in patients with type II diabetes. Diabetes 46: 854-859
27. Shin GT, Kim SJ, Ma KA, Kim HS, Kim D 2000 ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis 36: 894-902
28. Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ 2003 The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 60: 318-326
29. Tauxe WN, Dubovsky EV, Kidd T Jr, Diaz F, Smith LR 1982 New formulas for the calculation of effective renal plasma flow. Eur J Nucl Med 7: 51-54
30. Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, Goubina I, Fulcher G, Yue D, Jerums G 2004 The burden of anemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol Dial Transplant 19: 1792-1797
31. United States Renal Data System 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA